Perrigo (PRGO) Non-Current Debt (2013 - 2026)
Perrigo (PRGO) posted quarterly Non-Current Debt of $3.6 billion for Q1 2026, up 0.83% year-over-year from $3.6 billion in Q1 2025, and little changed quarter-over-quarter from $3.6 billion in Q4 2025.
Perrigo (PRGO) Non-Current Debt (2013 - 2026) Analysis & Trends
Perrigo (PRGO) has reported Non-Current Debt for 14 consecutive years, with $3.6 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Debt rose 0.83% year-over-year to $3.6 billion; the TTM figure through Mar 2026 stood at $3.6 billion (up 0.83% YoY), while the FY2025 annual figure was $3.6 billion, up 0.61% from the prior year.
- Non-Current Debt steadied at $3.6 billion in Q1 2026 per PRGO's latest filing, from $3.6 billion in the prior quarter.
- Across five years, Non-Current Debt topped out at $4.3 billion in Q3 2024 and bottomed at $3.5 billion in Q2 2022.
- Historically, Non-Current Debt has averaged $3.8 billion across 5 years, with a median of $3.6 billion in 2024.
- Annual changes were most pronounced in 2022 — Non-Current Debt soared 39.66% — and 2025, when it declined 16.34%.
- Perrigo's Non-Current Debt stood at $4.1 billion in 2022, then fell by 10.75% to $3.6 billion in 2023, then fell by 1.41% to $3.6 billion in 2024, then grew by 0.61% to $3.6 billion in 2025, then increased by 0.49% to $3.6 billion in 2026.
- Business Quant data shows PRGO's Non-Current Debt at $3.6 billion in Q1 2026, $3.6 billion in Q4 2025, and $3.6 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | -8.44 Bn |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.32 Bn | 2.15 Bn | 12.09 Bn |
| 3 | Zoetis | 31.53 Bn | 29.86 Bn | 1.05 Bn | 9.05 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 27.73 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | 11.61 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 3.85 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | 130.00 Mn |
| 10 | Perrigo | 1.94 Bn | 1.54 Bn | 313.90 Mn | 3.28 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 27, 2026 | 3.28 Bn |
| Mar 28, 2026 | 3.62 Bn |
| Dec 31, 2025 | 3.60 Bn |
| Sep 27, 2025 | 3.61 Bn |
| Jun 28, 2025 | 3.62 Bn |
| Mar 29, 2025 | 3.59 Bn |
| Dec 31, 2024 | 3.58 Bn |
| Sep 28, 2024 | 4.31 Bn |
| Jun 29, 2024 | 3.62 Bn |
| Mar 30, 2024 | 3.62 Bn |
| Dec 31, 2023 | 3.63 Bn |
| Sep 30, 2023 | 4.05 Bn |
| Jul 1, 2023 | 4.06 Bn |
| Apr 1, 2023 | 4.06 Bn |
| Dec 31, 2022 | 4.07 Bn |
| Oct 1, 2022 | 4.08 Bn |
| Jul 2, 2022 | 4.09 Bn |
| Apr 2, 2022 | 3.51 Bn |
| Dec 31, 2021 | 2.92 Bn |
| Oct 2, 2021 | 2.92 Bn |